News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Announces the Departure of Chief Commercial Officer
MONTREAL , Nov. 30, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the departure of Eric Grinstead as the Company’s chief
View HTML
Toggle Summary Clementia to Present at the Evercore ISI HealthCONx Conference
MONTREAL , Nov. 21, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins , Ph.D., chief executive officer and
View HTML
Toggle Summary Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates
Recent FDA Meeting Identifies Path Towards NDA Submission in the Second Half of 2019 Financing Raises $75 million to Support a Potential Commercial Launch MONTREAL , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company
View HTML
Toggle Summary Clementia Announces Pricing of Public Offering of Common Shares
MONTREAL , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the pricing of an underwritten public offering of 5,300,000
View HTML
Toggle Summary Clementia Announces Proposed Public Offering of Common Shares
MONTREAL , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that it intends to offer and sell, subject to market conditions,
View HTML
Toggle Summary Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results
Updated Regulatory Strategy Based on 12-Week Flare-up Data from Completed Phase 2 Program and Consultation with the FDA NDA Submission Planned for the Second Half of 2019 MONTREAL , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical
View HTML
Toggle Summary Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers
Data from Study Expected in Q1 2019 MONTREAL , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the initiation of a Phase 1
View HTML
Toggle Summary Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP
Updated 12-Week Flare-Up Data Presented at Mechanistic and Therapeutic Advances in Rare Skeletal Diseases and ASBMR 2018 Company Announces Additional Updated 12-Month WBCT Scan Data Data Continue to Support Treatment Potential of Palovarotene for People with FOP MONTREAL , Sept.
View HTML
Toggle Summary Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences
MONTREAL , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the company’s participation at the following upcoming
View HTML
Toggle Summary Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP
Enrollment Completed Four Months Ahead of Schedule; Two Interim Data Analyses On Track for 2019 MONTREAL , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage company innovating treatments for individuals with ultra-rare bone disorders and other
View HTML